CL2014002271A1 - Una solucion oftalmologica acuosa que comprende un agente inmunosupresor, preferiblemente ciclosporina a, un derivado de celulosa como primer polimero, un derivado de polivinilo como segundo polimero, un polimero con un grupo funcional lipofilico como tercer polimero; su proceso de preparacion, util para tratar trastornos de la superficie del ojo de base inflamatoria o inmunologica. - Google Patents

Una solucion oftalmologica acuosa que comprende un agente inmunosupresor, preferiblemente ciclosporina a, un derivado de celulosa como primer polimero, un derivado de polivinilo como segundo polimero, un polimero con un grupo funcional lipofilico como tercer polimero; su proceso de preparacion, util para tratar trastornos de la superficie del ojo de base inflamatoria o inmunologica.

Info

Publication number
CL2014002271A1
CL2014002271A1 CL2014002271A CL2014002271A CL2014002271A1 CL 2014002271 A1 CL2014002271 A1 CL 2014002271A1 CL 2014002271 A CL2014002271 A CL 2014002271A CL 2014002271 A CL2014002271 A CL 2014002271A CL 2014002271 A1 CL2014002271 A1 CL 2014002271A1
Authority
CL
Chile
Prior art keywords
polymer
derivative
inflammatory
eye
useful
Prior art date
Application number
CL2014002271A
Other languages
English (en)
Inventor
Fabrice Mercier
Emmanuel Muriaux
Original Assignee
Thea Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46298539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002271(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thea Lab filed Critical Thea Lab
Publication of CL2014002271A1 publication Critical patent/CL2014002271A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014002271A 2012-03-22 2014-08-27 Una solucion oftalmologica acuosa que comprende un agente inmunosupresor, preferiblemente ciclosporina a, un derivado de celulosa como primer polimero, un derivado de polivinilo como segundo polimero, un polimero con un grupo funcional lipofilico como tercer polimero; su proceso de preparacion, util para tratar trastornos de la superficie del ojo de base inflamatoria o inmunologica. CL2014002271A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261614218P 2012-03-22 2012-03-22
FR1252583A FR2988297B1 (fr) 2012-03-22 2012-03-22 Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur

Publications (1)

Publication Number Publication Date
CL2014002271A1 true CL2014002271A1 (es) 2014-11-03

Family

ID=46298539

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002271A CL2014002271A1 (es) 2012-03-22 2014-08-27 Una solucion oftalmologica acuosa que comprende un agente inmunosupresor, preferiblemente ciclosporina a, un derivado de celulosa como primer polimero, un derivado de polivinilo como segundo polimero, un polimero con un grupo funcional lipofilico como tercer polimero; su proceso de preparacion, util para tratar trastornos de la superficie del ojo de base inflamatoria o inmunologica.

Country Status (23)

Country Link
US (1) US8969305B2 (es)
EP (1) EP2827840B1 (es)
JP (1) JP6166341B2 (es)
KR (1) KR102021633B1 (es)
AR (1) AR090466A1 (es)
BR (1) BR112014019141A8 (es)
CA (1) CA2863000C (es)
CL (1) CL2014002271A1 (es)
CY (1) CY1122086T1 (es)
DK (1) DK2827840T3 (es)
ES (1) ES2746701T3 (es)
FR (1) FR2988297B1 (es)
HU (1) HUE045252T2 (es)
LT (1) LT2827840T (es)
MA (1) MA37297B1 (es)
MX (1) MX350799B (es)
PL (1) PL2827840T3 (es)
PT (1) PT2827840T (es)
RS (1) RS59324B1 (es)
RU (1) RU2634267C2 (es)
SI (1) SI2827840T1 (es)
UA (1) UA115141C2 (es)
WO (1) WO2013140071A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015093924A1 (es) * 2013-12-19 2015-06-25 CASTRO ALDRETE, Jorge Issac Vehículo para la administración de compuestos farmacéuticos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0558906A (ja) * 1991-09-06 1993-03-09 Sankyo Co Ltd シクロスポリン点眼製剤
JP3631490B2 (ja) * 1992-05-13 2005-03-23 ノバルティス ファーマ株式会社 シクロスポリン含有眼科用組成物
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
TR200302105T4 (tr) 2000-04-07 2004-02-23 Laboratoire Medidom S. A. Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
CN1127955C (zh) * 2000-07-07 2003-11-19 中山医科大学中山眼科中心 一种眼前段及眼表免疫相关性疾病治疗药物
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
WO2006073786A2 (en) * 2004-12-30 2006-07-13 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
EP2197461B1 (en) * 2007-10-08 2018-02-21 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
AU2008309923B2 (en) * 2007-10-08 2014-04-03 Fovea Pharmaceuticals Aqueous ophthalmic formulations
KR20100072333A (ko) * 2007-11-01 2010-06-30 보오슈 앤드 롬 인코포레이팃드 약물 전달을 위한 비히클로서의 비-수성 수혼화성 물질
WO2009088570A1 (en) * 2008-01-04 2009-07-16 Sirion Therapeutics, Inc. Stable aqueous cyclosporin compositions
CN101244035A (zh) * 2008-02-21 2008-08-20 南京医科大学附属南京第一医院 一种环孢菌素a眼用乳剂制剂及其制备方法
KR20120022574A (ko) * 2010-07-30 2012-03-12 주식회사종근당 사이클로스포린 에이 함유 점안제 조성물

Also Published As

Publication number Publication date
SI2827840T1 (sl) 2019-11-29
ES2746701T3 (es) 2020-03-06
EP2827840A1 (fr) 2015-01-28
KR102021633B1 (ko) 2019-09-16
PL2827840T3 (pl) 2019-12-31
UA115141C2 (uk) 2017-09-25
JP2015510921A (ja) 2015-04-13
MX350799B (es) 2017-09-25
HUE045252T2 (hu) 2019-12-30
FR2988297B1 (fr) 2014-03-28
AR090466A1 (es) 2014-11-12
FR2988297A1 (fr) 2013-09-27
WO2013140071A1 (fr) 2013-09-26
CA2863000A1 (fr) 2013-09-26
MA37297B1 (fr) 2017-01-31
US20130267472A1 (en) 2013-10-10
EP2827840B1 (fr) 2019-08-28
JP6166341B2 (ja) 2017-07-19
PT2827840T (pt) 2019-10-11
BR112014019141A2 (es) 2017-06-20
RU2634267C2 (ru) 2017-10-24
MX2014010270A (es) 2015-01-14
RS59324B1 (sr) 2019-10-31
MA37297A1 (fr) 2016-05-31
CA2863000C (fr) 2020-04-21
LT2827840T (lt) 2019-10-10
CY1122086T1 (el) 2020-11-25
KR20140136932A (ko) 2014-12-01
BR112014019141A8 (pt) 2017-07-11
RU2014134741A (ru) 2016-03-20
DK2827840T3 (da) 2019-09-30
US8969305B2 (en) 2015-03-03

Similar Documents

Publication Publication Date Title
CL2014003165A1 (es) Proceso mejorado para la preparación de treprostinil y derivados del mismo.
BR112017007301A2 (pt) estruturas fibrosas solúveis e métodos para a fabricação das mesmas
CL2015000873A1 (es) Métodos para el tratamiento del síndrome de alport.
JP2015512729A5 (es)
BR112015000527A2 (pt) agente reológico, métodos de preparação e usos dos mesmos.
JP2012143233A5 (es)
CL2015000501A1 (es) Nanopartícula polimérica de finasterida y minoxidil, proceso de preparación, suspensión acuosa conteniendo la misma, composición farmacéutica, y su uso.
JP2014010339A5 (es)
BR112014016505A2 (pt) conjunto e sistema de tratamento para síndrome do olho seco
MX360712B (es) Composición acondicionadora para telas.
JP2014517802A5 (es)
FI20126341A (fi) Menetelmä mikrofibrilloidun selluloosan valmistamiseksi, josta vesi on poistettu
MX2020004076A (es) Composiciones oftalmicas estabilizadas de omega 3.
CL2015001318A1 (es) Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras.
EP2841462B8 (en) Crosslinked hyaluronan derivative, method of preparation thereof, hydrogel and microfibers based thereon
BR112015010597A2 (pt) secagem mediante mistura de polissacarídeo nanofibrilado".
BR112016013316A8 (pt) método para a produção de furfural e uso de ácido metanossulfônico
CL2015000673A1 (es) Proceso para mejorar las propiedades reológicas de una dispersión acuosa
BR112015006533A2 (pt) método para a fabricação de um produto de polímero com características super- ou extremamente hidrofóbicas, um produto obtenível a partir do referido método e seu uso
CO6870047A2 (es) Soporte basado en fibras celulósicas y/o sintéticas, método para producirlo y uso del soporte
EP3198673A4 (en) Polymer solution, fiber mat, and nanofiber membrane-electrode-assembly therewith, and method of fabricating same
CL2014002831A1 (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos para tratar infestacion por helmintos.
EA201891505A1 (ru) Микрокапсула
CL2014003458A1 (es) Conjunto de rodamiento con casquillo de seguridad, comprende un casquillo de seguridad configurado a modo de anillo de dimensiones equivalentes a las dimensiones de unas unidades pre-montadas, conformado por cuatro superficies diferenciadas; y procedimiento de insercion de un conjunto de rodamiento.
MY169325A (en) A composition for preparation of viscoelastic crosslinked hyaluronic acid, and crosslinked hyaluronic acid obtained by using the same